Anti-helicobacter pylori infection lactobacillus reuteri and application thereof

The invention discloses lactobacillus reuteri capable of resisting helicobacter pylori infection and application of the lactobacillus reuteri. The lactobacillus reuteri is identified as lactobacillus reuteri, the strain name is DRTR, the lactobacillus reuteri is preserved in the China Center for Typ...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	SHI LINGYAN, LI PEIRU, JIA CHANGSHENG, ZHANG SHAOLUN, BIAN XULEI
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FOODS OR FOODSTUFFS FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL PROCESSES USING MICROORGANISMS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT THEIR TREATMENT, NOT COVERED BY OTHER CLASSES VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention discloses lactobacillus reuteri capable of resisting helicobacter pylori infection and application of the lactobacillus reuteri. The lactobacillus reuteri is identified as lactobacillus reuteri, the strain name is DRTR, the lactobacillus reuteri is preserved in the China Center for Type Culture Collection, the preservation date is October 19, 2020, and the preservation number is CCTCC NO: M2020597. The lactobacillus reuteri provided by the invention has good gastric acid resistance, can inhibit proliferation of helicobacter pylori and urease activity, and reduces adhesion of the helicobacter pylori to human gastric mucosa cells GES-1; the helicobacter pylori is prepared into a corresponding product for inhibiting helicobacter pylori infection, so that the growth of helicobacter pylori in a stomach environment can be inhibited; when the compound is combined with antibiotics to treat helicobacter pylori infection, the eradication rate can be remarkably increased, side effects in the treatment proc